Sheila Annie Peters

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat
    Sheila Annie Peters
    Global Compound Sciences, Computational Chemistry, AstraZeneca R and D, Pepparedsleden 1, 43183 Molndal, Sweden
    J Pharmacokinet Pharmacodyn 35:1-30. 2008
  2. ncbi Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles
    Sheila Annie Peters
    Discovery DMPK and Bioanalytical Chemistry, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 47:245-59. 2008
  3. ncbi Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis
    Sheila Annie Peters
    Discovery DMPK and Bioanalytical Chemistry, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 47:261-75. 2008
  4. ncbi Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization
    Sheila Annie Peters
    Discovery DMPK, AstraZeneca R and D, Molndal, Sweden
    Curr Opin Drug Discov Devel 12:509-18. 2009

Detail Information

Publications4

  1. ncbi Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat
    Sheila Annie Peters
    Global Compound Sciences, Computational Chemistry, AstraZeneca R and D, Pepparedsleden 1, 43183 Molndal, Sweden
    J Pharmacokinet Pharmacodyn 35:1-30. 2008
    ..The application of PBPK simulations in the early detection of gastric emptying problems with existing data and without the need to resort to additional animal studies, is appealing both from an economic and ethical standpoint...
  2. ncbi Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles
    Sheila Annie Peters
    Discovery DMPK and Bioanalytical Chemistry, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 47:245-59. 2008
    ....
  3. ncbi Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis
    Sheila Annie Peters
    Discovery DMPK and Bioanalytical Chemistry, AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 47:261-75. 2008
    ..The aim of this article is to evaluate the utility of PBPK models for simulating oral lineshapes by optimizing clearance and distribution parameters through fitting observed intravenous pharmacokinetic profiles...
  4. ncbi Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization
    Sheila Annie Peters
    Discovery DMPK, AstraZeneca R and D, Molndal, Sweden
    Curr Opin Drug Discov Devel 12:509-18. 2009
    ..Recent publications covering four important areas of the application of PBPK modeling in LO have been reviewed...